What is Hemanext?
Based in Massachusetts, Hemanext is a pioneering medical technology company dedicated to the innovation of red blood cell processing and storage. The company's proprietary technology is engineered to enhance the quality and longevity of blood products, addressing critical challenges in transfusion medicine. By focusing on the intersection of biotechnology and medical device engineering, Hemanext has established a unique competitive advantage, ensuring that healthcare providers can deliver safer, more effective blood components to patients in need. Its market position is defined by a commitment to rigorous clinical standards and the modernization of blood banking infrastructure.
How much funding has Hemanext raised?
Hemanext has raised a total of $130.9M across 10 funding rounds:
Private Equity
$12.3M
Private Equity
$2.7M
Debt
$2M
Debt
$350K
Series A
$15M
Series B
$18M
Multiple Rounds
$80.6M
Private Equity (2011): $12.3M, investors not publicly disclosed
Private Equity (2017): $2.7M, investors not publicly disclosed
Debt (2018): $2M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Antaeus Wealth Advisors
Series B (2022): $18M, investors not publicly disclosed
Private Equity (2025): $20M, investors not publicly disclosed
Stock/Share Issuance (2025): $18.9M, investors not publicly disclosed
Private Equity (2025): $21.7M, investors not publicly disclosed
Private Equity (2025): $20M, investors not publicly disclosed
Key Investors in Hemanext
Antaeus Wealth Advisors
An integrated investment and financial planning firm based in Boxborough, Massachusetts, providing customized financial guidance across market cycles.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Hemanext?
With the recent influx of capital, Hemanext is well-positioned to scale its manufacturing capabilities and expand its footprint in international markets. The strategic focus will likely shift toward optimizing supply chain efficiencies and deepening clinical research to support broader adoption of its processing technology. As the company navigates this growth phase, the emphasis remains on maintaining high-quality standards while scaling operations to meet the increasing demand for advanced blood storage solutions. Investors and industry observers will be monitoring the firm's ability to leverage this liquidity to drive long-term value and improve patient outcomes on a global scale.
See full Hemanext company page
